207 related articles for article (PubMed ID: 9131488)
1. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.
Spielberg SP
J Pharmacokinet Biopharm; 1996 Oct; 24(5):509-19. PubMed ID: 9131488
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
3. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism.
Cribb AE; Nakamura H; Grant DM; Miller MA; Spielberg SP
Biochem Pharmacol; 1993 Mar; 45(6):1277-82. PubMed ID: 8466547
[TBL] [Abstract][Full Text] [Related]
4. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic NATs and cancer predisposition.
Hirvonen A
IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
7. Human acetyltransferase polymorphisms.
Grant DM; Hughes NC; Janezic SA; Goodfellow GH; Chen HJ; Gaedigk A; Yu VL; Grewal R
Mutat Res; 1997 May; 376(1-2):61-70. PubMed ID: 9202739
[TBL] [Abstract][Full Text] [Related]
8. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.
Hein DW
Mutat Res; 2002 Sep; 506-507():65-77. PubMed ID: 12351146
[TBL] [Abstract][Full Text] [Related]
10. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
11. Acetylator status, drug metabolism and disease.
Pande JN; Pande A; Singh SP
Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
[TBL] [Abstract][Full Text] [Related]
12. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.
Zielińska E; Niewiarowski W; Bodalski J; Rebowski G; Skretkowicz J; Mianowska K; Sekulska M
Pharm World Sci; 1998 Jun; 20(3):123-30. PubMed ID: 9618736
[TBL] [Abstract][Full Text] [Related]
13. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors.
Rodrigues-Lima F; Dupret JM
Curr Pharm Des; 2004; 10(20):2519-24. PubMed ID: 15320760
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of the human arylamine N-acetyltransferases.
Grant DM; Goodfellow GH; Sugamori K; Durette K
Pharmacology; 2000 Sep; 61(3):204-11. PubMed ID: 10971207
[TBL] [Abstract][Full Text] [Related]
16. Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyl-transferase encoding genes of the Syrian hamster.
Ferguson RJ; Doll MA; Rustan TD; Hein DW
Pharmacogenetics; 1996 Feb; 6(1):55-66. PubMed ID: 8845861
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K; Ginsberg G; Hattis D; Johns DO; Guyton KZ; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):440-72. PubMed ID: 20183529
[TBL] [Abstract][Full Text] [Related]
18. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens.
Hein DW; Doll MA; Rustan TD; Gray K; Ferguson RJ; Feng Y
Toxicol Appl Pharmacol; 1994 Jan; 124(1):16-24. PubMed ID: 8291057
[TBL] [Abstract][Full Text] [Related]
19. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity.
O'Neil WM; MacArthur RD; Farrough MJ; Doll MA; Fretland AJ; Hein DW; Crane LR; Svensson CK
J Clin Pharmacol; 2002 Jun; 42(6):613-9. PubMed ID: 12043950
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
